Keyword Analysis & Research: remix therapeutics


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
remix therapeutics0.110.555025318
remix0.420.27573155
therapeutics1.560.432069412

Keyword Research: People who searched remix therapeutics also searched

Keyword CPC PCC Volume Score
remix therapeutics1.960.2828281
remix therapeutics stock1.320.7792140
remix therapeutics myb0.360.4402598
remix therapeutics address0.040.8253529
remix therapeutics pipeline1.910.8462182
remix therapeutics cambridge1.831696872
remix therapeutics crunchbase0.370.8732276
remix therapeutics watertown ma1.070.45213
remix therapeutics jobs1.350.9415663
remix therapeutics news0.710.7823853
remix therapeutics pitchbook1.620.2851528
remix therapeutics phone number1.980.6296057
remix therapeutics inc1.320.6458613

Search Results related to remix therapeutics on Search Engine

  • Home - Remix Therapeutics

    remixtx.com

    https://www.remixtx.com/

    WEBFeb 1, 2024 · Remix™ launched in 2020 with a vision to transform patient's lives through modulation of RNA processing. Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins.

    DA: 12 PA: 86 MOZ Rank: 58

  • Our Science - Remix Therapeutics

    remixtx.com

    https://www.remixtx.com/science/

    WEBDetermined to deliver novel and impactful treatments, Remix™ sets about advancing our breakthrough discoveries into innovative and relevant medicines. Our first act is tackling previously undrugged oncogenic transcription factors to eradicate certain solid tumors and hematological malignancies.

    DA: 46 PA: 43 MOZ Rank: 62

  • About Us - Remix Therapeutics

    remixtx.com

    https://www.remixtx.com/about/

    WEBOur breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic.

    DA: 71 PA: 90 MOZ Rank: 87

  • Remix Therapeutics Closes $60 Million Financing to Advance …

    prnewswire.com

    https://www.prnewswire.com/news-releases/remix-therapeutics-closes-60-million-financing-to-advance-rem-422-pipeline-of-small-molecule-therapies-designed-to-reprogram-rna-processing-to-treat-disease-302024984.html

    WEBCAMBRIDGE, Mass., Jan. 3, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the...

    DA: 16 PA: 40 MOZ Rank: 19

  • Remix Therapeutics to Present Preclinical Data Demonstrating …

    prnewswire.com

    https://www.prnewswire.com/news-releases/remix-therapeutics-to-present-preclinical-data-demonstrating-myb-mrna-degradation-in-aml-at-the-65th-american-society-of-hematology-annual-meeting-and-exposition-ash-302008446.html

    WEBDec 7, 2023 · Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster ™ technology platform facilitates...

    DA: 73 PA: 76 MOZ Rank: 60


  • First small-molecule drug targeting RNA gains momentum

    nature.com

    https://www.nature.com/articles/s41587-020-00788-1

    WEBJan 11, 2021 · Remix Therapeutics, the latest such contender to emerge, disclosed an $81 million series A round on 8 December and unveiled plans to develop oral drugs that target and reprogram cells’ RNA...

    DA: 82 PA: 45 MOZ Rank: 32

  • Remix Therapeutics™ Closes $60 Million Financing to Advance …

    remixtx.com

    https://www.remixtx.com/remix-therapeutics-closes-60-million-financing-to-advance-rem-422-pipeline-of-small-molecule-therapies-designed-to-reprogram-rna-processing-to-treat-disease/

    WEBCambridge, Mass. (January 3, 2024) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the close of a $60 million financing led by The Column Group.

    DA: 53 PA: 56 MOZ Rank: 23

  • Remix Therapeutics Enters Collaboration with Roche for the …

    prnewswire.com

    https://www.prnewswire.com/news-releases/remix-therapeutics-enters-collaboration-with-roche-for-the-discovery-and-development-of-small-molecule-therapeutics-modulating-rna-processing-302024970.html

    WEBJan 3, 2024 · Remix Therapeutics is a clinical stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster ™ technology platform...

    DA: 15 PA: 68 MOZ Rank: 7

  • Remix Therapeutics raises $70m to develop drugs that …

    bostonglobe.com

    https://www.bostonglobe.com/2022/05/17/business/remix-therapeutics-raises-70m-develop-drugs-that-reprogram-rna/

    WEBMay 17, 2022 · The Cambridge startup says the new round of funding will carry it into 2024. By Ryan Cross Globe Staff,Updated May 17, 2022, 7:00 a.m. A scientist at Remix Therapeutics, based in Kendall Square ...

    DA: 98 PA: 18 MOZ Rank: 85

  • Remix Therapeutics | LinkedIn

    linkedin.com

    https://www.linkedin.com/company/remix-therapeutics

    WEBWatertown, MA, MA 5,346 followers. Reprogramming RNA Processing, Designing Therapeutic Solutions. View all 66 employees. About us. Remix launched in 2020 with a vision to transform patient's...

    DA: 84 PA: 52 MOZ Rank: 88